Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
06 February 2024 - 6:35AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2024
Commission File No. 001-35193
Grifols, S.A.
(Translation of registrant’s name into English)
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles 08174
Barcelona, Spain
(Address of registrant’s principal executive
office)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F
x Form 40-F ¨
Grifols, S.A.
TABLE OF CONTENTS
| Grifols, S.A.
Avinguda de la Generalitat 152-158
08174 Sant Cugat del Vallès
Barcelona - SPAIN
Tel. [34] 935 710 500
Fax [34] 935 710 267
www.grifols.com
Pursuant to the provisions of Article 227 of Law 6/2023 of March 17, on Securities Markets and
Investment Services, Grifols, S.A. ("Grifols" or the "Company") hereby informs about the
following
OTHER RELEVANT INFORMATION
Grifols announces the following changes in its corporate governance structure:
Raimon Grifols and Víctor Grifols Deu have decided to transition out of their executive
positions, Chief Corporate Officer and Chief Operating Officer, respectively, and will remain
on the Grifols Board, now as proprietary directors
Thomas Glanzmann continues as Executive Chairman.
The Board of Directors will appoint Nacho Abia as Chief Executive Officer (CEO).
The moves are part of a long-planned, carefully architected corporate governance evolution
strategy that Raimon Grifols and Víctor Grifols Deu initiated in 2022, together with the Board,
to steadily separate ownership from company management, setting a new standard for family
businesses listed on the Spanish Stock Exchange
Nacho Abia is an accomplished senior executive with 25 years of international management
experience at publicly traded life-science and medical-technology companies, will assume his
responsibilities on April 1, 2024. He was most recently Executive Officer and Global Chief
Strategy Officer of Tokyo-based Olympus Corporation, a Nikkei-listed company with 33,000
employees that specializes in medical technology and is a global leader in diagnostics and
minimally invasive treatments.
He will be appointed Board member on February 26 (by cooptation, covering a current vacancy)
and will assume his responsibilities as CEO on April 1, focusing on enhancing Grifols’ current
growth strategy, furthering operational excellence and continuing to execute the company’s
deleveraging plan.
Nacho Abia becoming CEO as well as the decision by Raimon Grifols and Víctor Grifols Deu to
step down from their current roles after a smooth transition are part of a succession roadmap that
the two Grifols executives, along with the Board, set in motion back in 2022. The Board awaited
activation until the company’s post-pandemic recovery had solidified. Well-orchestrated
handoffs transition will take place to ensure appropriate knowledge transfers, organizational
adaption, and smooth continuity of business operations.
This process began in earnest in the first months of 2023, when Thomas Glanzmann became
Executive Chairman then CEO, and Raimon Grifols and Víctor Grifols Deu took on their current
responsibilities. At that time the selection process for a new CEO accelerated. In December 2023,
Victor Grifols Roura retired from the Board and was substituted by Albert Grifols Coma-Cros.
Grifols, which has pioneered so many innovations over the decades, now also sets a new
corporate governance standard for family businesses listed on the Spanish Stock Exchange. |
| The Board, which is fully supportive of the company’s deliberate, stepwise approach to
leadership succession, was instrumental in the search for a new CEO.
In Barcelona, on February 5, 2024
Nuria Martín Barnés
Secretary of the Board of Directors |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
Grifols, S.A. |
|
|
|
|
|
|
|
By: |
/s/ David I. Bell |
|
|
Name: |
David I. Bell |
|
|
Title: |
Authorized Signatory |
Date: February 5, 2024
Grifols (PK) (USOTC:GIKLY)
Historical Stock Chart
From May 2024 to Jun 2024
Grifols (PK) (USOTC:GIKLY)
Historical Stock Chart
From Jun 2023 to Jun 2024